Market Survey Shows Potential of JAK Inhibitors to Treat IBD

Market Survey Shows Potential of JAK Inhibitors to Treat IBD
Directors from pharmaceutical and health insurance companies and gastroenterologists in the United States have expressed a positive opinion overall about the use of janus kinase (JAK) inhibitors for the treatment of inflammatory bowel disease (IBD), according to a recent survey. In the United States, TNF-α inhibitors, such as Remicade (infliximab) and Humira (adalimumab), are commonly used to treat ulcerative colitis and Crohn’s disease. However, the development of new therapies has brought alternative options to the market, especially for patients who do not respond to or cannot receive TNF-α inhi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *